2023 Fiscal Year Final Research Report
Development of an novel treatment for "Anticancer drug-induced cardiomyopathy" by utilizing the physiological effects of ghrelin
| Project/Area Number |
20K08505
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53020:Cardiology-related
|
|---|
| Research Institution | Yokohama City University (2023)
National Cardiovascular Center Research Institute (2020-2022) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 抗癌剤誘発性心筋症 / 心不全 / グレリン / ペプチドホルモン |
|---|
| Outline of Final Research Achievements |
Doxorubicin (DOX) is an anticancer drug used in the treatment of malignant lymphoma and breast cancer. Ghrelin is a peptide hormone synthesized in the stomach and has effects of stimulating feeding and the secretion of growth hormone and IGF-1. In this study, we examined the effects of ghrelin administration on cardiac function in a mouse model of doxorubicin-induced cardiomyopathy. As a result, 3 weeks of ghrelin administration (200 μg/kg/day by subcutaneous injection) suppressed doxorubicin-induced cardiac dysfunction as assessed by echocardiography. These results suggest that ghrelin may have a protective effect against doxorubicin-induced cardiomyopathy.
|
| Free Research Field |
循環器病学
|
| Academic Significance and Societal Importance of the Research Achievements |
近年、癌薬物療法は飛躍的な発展を遂げた。一方で抗癌剤は様々な頻度・重症度で、心筋障害・心機能低下を引き起こす。このため、昨今「Onco-Cardiology：腫瘍循環器学」という学問分野が立ち上がった。ドキソルビシン(DOX)は、悪性リンパ腫・乳癌等の治療に用いられている抗癌剤だが、不可逆的な心毒性を来すことがあり、癌ではなく心不全で亡くなる患者が存在する。よってDOX誘発性心筋症に対する画期的な治療法・予防法が望まれている。本研究は生体内で恒常的に産生されているペプチドホルモンであるグレリンが、DOX誘発性心筋症の予防的効果を有する可能性を示したものであり、その学術的・社会的意義は大きい。
|
